非小细胞肺癌中CD133+/巢蛋白+假定癌症干细胞的鉴定
Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer.
作者信息
Janikova Maria, Skarda Jozef, Dziechciarkova Marta, Radova Lenka, Chmelova Jana, Krejci Veronika, Sedlakova Eva, Zapletalova Jana, Langova Katerina, Klein Jiri, Grygarkova Ivona, Kolek Vitezslav
机构信息
Department of Pathology and Laboratory of Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, University Hospital Olomouc, Czech Republic.
出版信息
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;154(4):321-6. doi: 10.5507/bp.2010.048.
AIMS
No effective treatment for lung cancer exists currently. One reason for this, is the development of drug resistance, assumed to be associated with cancer stem cell (CSCs) emergence within the tumour. This pilot study aimed to identify CSCs in 121 non-small cell lung cancer (NSCLC) patient samples via detection of the expression of stem cell markers - CD133 and nestin.
MATERIAL AND METHODS
Archived paraffin blocks of 121 patient samples were prepared as Tissue Microarrays (TMA). Indirect immunohistochemical staining was used to determine the level of expression of CD133 and nestin. Double immunofluorescence staining was used to investigate the co-expression of these two markers. To determine the correlation between expression of nestin and CD133 with the length of asymptomatic period and overall patient survival we used the Kaplan-Meyer analysis.
RESULTS
CD133 expression was detected in 22 (19%), nestin in the epithelium in 74 (66%) and vasculature in 78 (70%) of patients. Co-expression of these two markers was found in 21 (17%) patients in less than 1% of positive cells without impact on disease free or overall survival.
CONCLUSIONS
We identified CD133(+)/nestin(+) cells as novel potential markers of lung cancer CSCs.
目的
目前尚无有效的肺癌治疗方法。其中一个原因是耐药性的产生，据推测这与肿瘤内癌症干细胞（CSCs）的出现有关。这项初步研究旨在通过检测干细胞标志物CD133和巢蛋白的表达，在121例非小细胞肺癌（NSCLC）患者样本中鉴定癌症干细胞。
材料与方法
将121例患者样本的存档石蜡块制备成组织微阵列（TMA）。采用间接免疫组织化学染色法测定CD133和巢蛋白的表达水平。采用双重免疫荧光染色法研究这两种标志物的共表达情况。为了确定巢蛋白和CD133的表达与无症状期长度和患者总生存期之间的相关性，我们使用了Kaplan-Meier分析。
结果
在22例（19%）患者中检测到CD133表达，74例（66%）患者的上皮细胞中检测到巢蛋白表达，78例（70%）患者的脉管系统中检测到巢蛋白表达。在21例（17%）患者中发现这两种标志物的共表达，阳性细胞少于1%，且对无病生存期或总生存期无影响。
结论
我们将CD133(+)/巢蛋白(+)细胞鉴定为肺癌癌症干细胞的新型潜在标志物。
Zotero 插件